Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $47.5 million.

  • Celldex Therapeutics' Total Non-Current Liabilities rose 4062.6% to $47.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.5 million, marking a year-over-year increase of 4062.6%. This contributed to the annual value of $41.9 million for FY2024, which is 3060.24% up from last year.
  • Celldex Therapeutics' Total Non-Current Liabilities amounted to $47.5 million in Q3 2025, which was up 4062.6% from $34.5 million recorded in Q2 2025.
  • Celldex Therapeutics' Total Non-Current Liabilities' 5-year high stood at $47.5 million during Q3 2025, with a 5-year trough of $15.4 million in Q1 2022.
  • Over the past 5 years, Celldex Therapeutics' median Total Non-Current Liabilities value was $26.8 million (recorded in 2024), while the average stood at $26.2 million.
  • As far as peak fluctuations go, Celldex Therapeutics' Total Non-Current Liabilities skyrocketed by 10418.6% in 2022, and later tumbled by 4660.83% in 2023.
  • Over the past 5 years, Celldex Therapeutics' Total Non-Current Liabilities (Quarter) stood at $17.8 million in 2021, then grew by 18.93% to $21.2 million in 2022, then soared by 51.21% to $32.1 million in 2023, then skyrocketed by 30.6% to $41.9 million in 2024, then grew by 13.55% to $47.5 million in 2025.
  • Its last three reported values are $47.5 million in Q3 2025, $34.5 million for Q2 2025, and $33.9 million during Q1 2025.